[New management of phosphocalcic abnormalities in dialysis patient]. / Nouveautés dans la prise en charge des anomalies du bilan phosphocalcique chez le patient dialysé.

Disorders of the phosphocalcic metabolism are frequent in dialysis patients. Such disorders are difficult to treat and have negative impact on bone health, but also on cardiovascular mortality. Hyperphosphoremia is a strong predictor of cardiovascular mortality. New phosphate binders are now available in Belgium. A new molecule acting on the calcium receptor of the parathyroid glands is able to control secondary and tertiary hyperparathyroidism in dialysis patients. These new therapies, specific for dialysis patients, will be reviewed in this article.

[News in the management of calcium and phosphorus metabolism disorders for patient treated by hemodialysis]. / Nouveautés dans la prise en charge médicale des anomalies du bilan phosphocalcique chez le patient hémodialysé.

Bone metabolism is very frequently disturbed in end stage renal failure hemodialyzed, with secondary hyperparathyroidism development but also serious potential cardiovascular consequences. New treatments will be available very soon in Europe such as new phosphate binders, vitamin D2 analogues or calcimimetics to fight against such medical diseases, with the hope of less risk for vascular complications. The real place of such new medical opportunities needs to be determined. Moreover, studies with morbidity and mortality end-points are waited before estimating the real importance of these new therapeutic tools.

[Coenzyme Q10: biochemistry, pathophysiology of its deficiency and potential benefit of an increased intake]. / Le coenzyme Q10: biochimie, physiopathologie de sa carence et intérêt potentiel d'une augmentation de ses apports.

After a brief reminding of the synthesis and function of coenzyme Q10, this article tries to summarise the current state of knowledge about the consequences of its deficiency and about the potential benefits of an increased intake of this coenzyme. We then describe the arguments in favour of such an increase in cardiac diseases and in Parkinson's disease.